Literature DB >> 7642874

Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.

F Chézalviel-Guilbert1, J M Davy, J M Poirier, J Weissenburger.   

Abstract

OBJECTIVES: The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias.
BACKGROUND: The utility of sotalol is limited by proarrhythmia related to excessive delays in repolarization. The addition of mexiletine may limit the risk of torsade de pointes because it reduced in vitro the sotalol-induced increase in action potential duration.
METHODS: Two studies were performed in eight hypokalemic dogs (plasma potassium level < or = 3.2 mmol/liter) with chronic atrioventricular block (mean ventricular cycle length, RR 1,100 ms) at 3-day intervals using a crossover protocol. Intravenous sotalol (4.5 + 1.5 mg/kg body weight per h) alone was given for 2 h, or, on another day, an intravenous mexiletine infusion (4.5 + 1.5 mg/kg per h) was begun 30 min before sotalol infusion. Spontaneous ventricular cycle length and QT interval and ventricular effective refractory period at the 1,000-ms pacing cycle length were measured at baseline and 30 min after the onset of each drug infusion. The electrocardiogram (ECG) was continuously monitored for torsade de pointes.
RESULTS: Sotalol plus mexiletine and sotalol alone had a significant (p < or = 0.05) and similar effect on ventricular cycle length (+ 800 +/- 93 vs. + 690 +/- 104 ms [mean +/- SEM]) and ventricular effective refractory period (+ 20 +/- 4 vs. + 25 +/- 4 ms), but sotalol plus mexiletine had a lesser effect on QT interval (+ 20 +/- 6 vs. + 50 +/- 8 ms, p < or = 0.05). Torsade de pointes is less frequent (one of eight dogs vs. six of eight dogs, p = 0.02) with sotalol plus mexiletine than with sotalol alone.
CONCLUSIONS: The coadministration of a class Ib agent can reduce the proarrhythmic potential of a class III drug in experimental animals predisposed to torsade de pointes arrhythmias and further suggests the clinical utility of such a strategy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642874     DOI: 10.1016/0735-1097(95)00234-U

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

Authors:  L Johannesen; J Vicente; J W Mason; C Erato; C Sanabria; K Waite-Labott; M Hong; J Lin; P Guo; A Mutlib; J Wang; W J Crumb; K Blinova; D Chan; J Stohlman; J Florian; M Ugander; N Stockbridge; D G Strauss
Journal:  Clin Pharmacol Ther       Date:  2015-11-28       Impact factor: 6.875

3.  Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats.

Authors:  Guilda Sarraf; Terrance D Barrett; Michael J A Walker
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

4.  Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.

Authors:  C Lengyel; A Varró; K Tábori; J G Papp; I Baczkó
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

5.  Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment.

Authors:  Kelly C Chang; Sara Dutta; Gary R Mirams; Kylie A Beattie; Jiansong Sheng; Phu N Tran; Min Wu; Wendy W Wu; Thomas Colatsky; David G Strauss; Zhihua Li
Journal:  Front Physiol       Date:  2017-11-21       Impact factor: 4.566

Review 6.  Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).

Authors:  David G Strauss; Wendy W Wu; Zhihua Li; John Koerner; Christine Garnett
Journal:  Clin Pharmacol Ther       Date:  2021-01-07       Impact factor: 6.875

Review 7.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

8.  Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.

Authors:  Adam P Hill; Matthew D Perry; Najah Abi-Gerges; Jean-Philippe Couderc; Bernard Fermini; Jules C Hancox; Bjorn C Knollmann; Gary R Mirams; Jon Skinner; Wojciech Zareba; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-06-09       Impact factor: 5.182

Review 9.  Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.

Authors:  Jose Vicente; Robbert Zusterzeel; Lars Johannesen; Jay Mason; Philip Sager; Vikram Patel; Murali K Matta; Zhihua Li; Jiang Liu; Christine Garnett; Norman Stockbridge; Issam Zineh; David G Strauss
Journal:  Clin Pharmacol Ther       Date:  2017-11-16       Impact factor: 6.875

10.  Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.

Authors:  Jose Vicente; Robbert Zusterzeel; Lars Johannesen; Roberto Ochoa-Jimenez; Jay W Mason; Carlos Sanabria; Sarah Kemp; Philip T Sager; Vikram Patel; Murali K Matta; Jiang Liu; Jeffry Florian; Christine Garnett; Norman Stockbridge; David G Strauss
Journal:  Clin Pharmacol Ther       Date:  2019-01-18       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.